SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001104659-22-046052
Filing Date
2022-04-14
Accepted
2022-04-14 16:30:26
Documents
7
Period of Report
2022-04-14

Document Format Files

Seq Description Document Type Size
1 PRE 14A tm2212755d1_pre14a.htm PRE 14A 447270
2 GRAPHIC tm2212755d1_pre14aimg001.jpg GRAPHIC 109493
3 GRAPHIC tm2212755d1_pre14aimg002.jpg GRAPHIC 182407
4 GRAPHIC tm2212755d1_pre14asp1img001.jpg GRAPHIC 4738
5 GRAPHIC tm2212755d1_pre14asp1img002.jpg GRAPHIC 2075
6 GRAPHIC tm2212755d1_pre14asp1img003.jpg GRAPHIC 2075
7 GRAPHIC tm2212755d1_pre14asp4img001.jpg GRAPHIC 4369
  Complete submission text file 0001104659-22-046052.txt   860926
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

IRS No.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-33357 | Film No.: 22827652
SIC: 2836 Biological Products, (No Diagnostic Substances)